Terms & Conditions

Terms of Use Last updated: May 04, 2022 Please read these terms and conditions carefully before using Our Website. Interpretation and Definitions Interpretation The words of which the initial letter is capitalized have meanings defined under the following conditions. The following definitions shall have the same meaning regardless of whether they appear in singular or […]

News

News APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending on Disease Progression of Alzheimer’s Disease December 10, 2024 APRINOIA Therapeutics Reported a Novel Oligomer Tau Assay System with APNmAb005 Antibody, Successfully Detected the Target Molecule of Oligomer Tau Species and Elucidated the Increases Depending […]

Contact Us

Contact Us Get in Touch If you would like to learn more about APRINOIA, we would love to hear from you. Click the links in the Contact Info section or complete the form below. Contact Info Hong KongUnit 513, 5/F, Enterprise Place,Phase One, Hong Kong Science Park,Pak Shek Kok, N.T. Hong Kong SuzhouR503, 5F, Building […]

Patients

Patients Neurodegenerative Diseases The Threat to Human Health Approximately 50M people worldwide suffer from Alzheimer’s disease.  An estimated 130M people will be diagnosed with AD by 2050. Approximately 10M people are affected by Parkinson’s disease (PD). Tauopathies and alpha-synucleinopathies play a critical role in a range of neurodegenerative diseases. Tau can accumulate in different parts […]

Our Pipeline

Our Pipeline We have several diagnostic and therapeutic programs focused on a range of neurodegenerative diseases. Program Indication(s) Discovery Preclinical Phase 1 Phase 2 Phase 3 [18F]-APN-1607 florzolotau (18F) Alzheimer’s & Tauopathies (e.g., PSP, FTD) China USA Read More [18F]-APN-1607 (florzolotau (18F)) is a new generation tau PET imaging tracer with a largely improved off-target […]

Our Science

Our Science Our Focus Neurodegenerative diseases are relentless, often fatal, and affect a range of cognitive, behavioral, and motor functions as basic as memory, thinking, speaking, walking, and breathing. A lack of accurate diagnostics has challenged therapeutic development for these conditions because our understanding of the underlying disease pathophysiology remains incomplete and there are no […]

About Us

About Us Our Mission We are a clinical stage biotech company committed to protecting patients’ brain health and changing outcomes for a broad range of neurodegenerative diseases through best-in-class diagnostic tools and novel therapies. Our name, APRINOIA, merges the Latin word for sunlight, “apricum,” with the Greek suffix for the mind, “noia.” Our name reflects […]

APRINOIA Therapeutics Completed $40 Million Series C Financing in 2021

APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP).

APRINOIA Therapeutics Selected and Joined JLABS @ Shanghai

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai. For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.